Olysio

Olysio is a prescription medication used with other antiviral medicines to treat chronic hepatitis C virus genotype 1 infection (a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure). 

Olysio belongs to a group of drugs called protease inhibitors that block a specific protein needed by the hepatitis C virus to replicate.

This medication comes in capsule form and is taken once daily with food. Swallow Olysio capsules whole. The recommended duration of treatment with Olysio is 12 weeks in combination with peginterferon alfa and ribavirin. 

Olysio can also be given with sofosbuvir for the treatment of chronic hepatitis C virus infection.

The most common side effects of Olysio in combination with peginterferon-alfa and ribavirin are rash (including photosensitivity), itching and nausea. Limit sun exposure and use sun protective measures during treatment.

Olysio is a prescription medication used with other antiviral medications to treat chronic hepatitis C (CHC) infection. 

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

The recommended dose of Olysio is one capsule of 150 mg taken orally once daily with food.

• The recommended duration of treatment is 12 weeks.

• The recommended duration of treatment is 12 weeks for patients without cirrhosis.
• The recommended duration of treatment is 24 weeks for patients with cirrhosis.

There is a risk of hepatitis B virus (HBV) becoming an active infection in those who have a current or previous infection with HBV and is treated with a certain antiviral medication (a direct-acting antiviral) to treat hepatitis C virus. Your healthcare provider will screen and monitor for HBV in those taking a direct-acting antiviral. Tell your healthcare provider if you have a history of hepatitis B infection or other liver problems before you are treated for hepatitis C. 

• Olysio in combination with peginterferon alfa and ribavirin may cause birth defects or death of your unborn baby. See "Pregnancy" section.
• Olysio in combination with peginterferon alfa and ribavirin may cause rashes and skin reactions to sunlight. These rashes and skin reactions to sunlight can be severe and you may need to be treated in a hospital. Rashes and skin reactions to sunlight are most common during the first 4 weeks of treatment, but can happen at any time during treatment with Olysio, peginterferon alfa, and ribavirin combination therapy.
  • Use sunscreen, and wear a hat, sunglasses, and protective clothing when you will be exposed to sunlight during treatment with Olysio.
  • Limit sunlight exposure during treatment with Olysio.
  • Avoid use of tanning beds, sunlamps, or other types of light therapy during treatment with Olysio.
  • Call your healthcare provider right away if you get any of the following symptoms:
    • burning, redness, swelling or blisters on your skin
    • mouth sores or ulcers
    • red or inflamed eyes, like "pink eye" (conjunctivitis)

Contact your healthcare provider immediately if you develop weakness, fatigue, nausea, vomiting, yellow eyes or skin, loss of appetite, or light-colored stools. These may be signs and symptoms of a serious liver problem. 

• Do not take Olysio alone. Olysio should be used together with peginterferon alfa and ribavirin or used in combination with Olysio to treat chronic hepatitis C infection.

The most common side effects of Olysio when used in combination with peginterferon alfa and ribavirin include:

• skin rash
• itching
• nausea

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of Olysio. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Tell your healthcare provider about the medications you take including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:

• amiodarone (Cordarone, Pacerone),
• amlodipine (Norvasc),
• atazanavir (Reyataz),
• atorvastatin (Lipitor, Caduet),
• carbamazepine (Carbatrol, Epitol, Equetro, Tegretol),
• clarithromycin (Biaxin, Prevpac),
• cobicistat-containing medicine: (Stribild),
• cyclosporine (Gengraf, Neoral, Sandimmune),
• darunavir (Prezista),
• delavirdine mesylate (Rescriptor),
• dexamethasone 
• digoxin (Lanoxin), 
• diltiazem (Cardizem, Tiazac),
• disopyramide (Norpace),
• efavirenz (Sustiva, Atripla), 
• erythromycin (E.E.S., Eryc, Ery-Tab, Erythrocin, Erythrocin Stearate),
• etravirine (Intelence),
• felodipine (Plendil),
• flecainide (Tambocor),
• fluconazole (Diflucan),
• fosamprenavir (Lexiva),
• indinavir (Crixivan),
• itraconazole (when taken by mouth) (Sporanox, Onmel),
• ketoconazole (when taken by mouth) (Nizoral),
• lopinavir (Kaletra),
• lovastatin (Advicor, Altoprev, Mevacor),
• mexiletine (Mexitil),
• midazolam 
• milk thistle (Silybum marianum) or products containing milk thistle,
• nelfinavir (Viracept),
• nevirapine (Viramune, Viramune XR),
• nicardipine (Cardene), 
• nifedipine (Adalat CC, Afeditab CR, Procardia),
• nisoldipine (Sular),
• oxcarbazepine (Trileptal),
• phenobarbital (Luminal), 
• phenytoin (Dilantin, Phenytek),
• pitavastatin (Livalo), 
• posaconazole (when taken by mouth) (Noxafil),
• pravastatin (Pravachol),
• propafenone (Rythmol SR),
• quinidine 
• rifabutin (Mycobutin),
• rifampin 
• rifapentine (Priftin),
• ritonavir (Norvir),
• rosuvastatin (Crestor), 
• saquinavir mesylate (Invirase),
• sildenafil (Revatio, Viagra), 
• simvastatin (Zocor, Vytorin, Simcor),
• sirolimus (Rapamune),
• St. John's wort (Hypericum perforatum) or products containing St. John's wort, 
• tacrolimus (Prograf),
• tadalafil (Adcirca, Cialis), 
• telithromycin (Ketek),
• tipranavir (Aptivus), 
• triazolam (when taken by mouth) (Halcion),  
• verapamil (Calan, Covera-HS, Isoptin, Tarka),
• voriconazole (Vfend), 
• warfarin (Coumadin)

This is not a complete list of Olysio drug interactions. Ask your healthcare provider or pharmacist for more information.

• Olysio in combination with peginterferon alfa and ribavirin may cause birth defects or death of your unborn baby. If you are pregnant or your sexual partner is pregnant, or plans to become pregnant, do not take these medicines. You or your sexual partner should not become pregnant while taking Olysio with peginterferon alfa and ribavirin and for 6 months after treatment is over.
  • Females and males must use two effective forms of birth control during treatment and for 6 months after treatment with Olysio, peginterferon alfa, and ribavirin combination therapy. Talk to your healthcare provider about forms of birth control that may be used during this time.
  • Females must have a pregnancy test before starting treatment with Olysio, peginterferon alfa, and ribavirin combination therapy, every month while being treated, and every month for 6 months after your treatment with Olysio, peginterferon alfa, and ribavirin combination therapy is over.
  • If you or your female sexual partner becomes pregnant while taking Olysio, peginterferon alfa, and ribavirin combination therapy or within 6 months after you stop taking these medicines, tell your healthcare provider right away. You or your healthcare provider should contact the Ribavirin Pregnancy Registry by calling 1-800-593-2214. The Ribavirin Pregnancy Registry collects information about what happens to mothers and their babies if the mother takes ribavirin while she is pregnant.

Tell your healthcare provider if you are breastfeeding. It is not known if Olysio passes into your breast milk. You and your healthcare provider should decide if you will take Olysio or breastfeed. You should not do both.

Limit sun exposure and use sun protective measures during treatment.

Females and males must use two effective forms of birth control during treatment and for 6 months after treatment with Olysio, peginterferon alfa, and ribavirin combination therapy.